Penumbra Reports 14.9% Revenue Growth in Q2 as Boston Scientific Acquisition Looms
The thrombectomy company posted $390 million in quarterly revenue and $34.8 million in net income, but suspended guidance and earnings calls amid pending acquisition.
Strong Q2 Performance Overshadowed by Acquisition
Penumbra, Inc. reported second quarter 2026 revenue of $390.0 million, representing a 14.9% increase compared to the same period in 2025, according to an 8-K filing with the Securities and Exchange Commission (8-K filing, 2026-07-30). The Alameda, California-based medical device company, which describes itself as "the world's leading thrombectomy company," also posted net income of $34.8 million for the quarter ended June 30, 2026.
The company's gross profit margin expanded to 67.9% in the second quarter, an improvement of 1.9 percentage points year-over-year (8-K filing, 2026-07-30). Income from operations reached $41.0 million during the period.
Business Segment Performance
Penumbra's core thrombectomy segment generated global revenue of $259.0 million in the second quarter, up 12.5% compared to Q2 2025 (8-K filing, 2026-07-30). The company's embolization and access business line showed stronger growth, with global revenue of $131.1 million representing a 20.0% year-over-year increase.
Total operating expenses for the quarter amounted to $223.9 million, comprising research and development costs of $25.4 million and selling, general and administrative expenses of $198.5 million (8-K filing, 2026-07-30). Notably, the SG&A figure included $6.9 million in acquisition-related expenses associated with the pending acquisition by Boston Scientific Corporation.
Guidance and Conference Call Suspended
In a departure from standard practice, Penumbra announced it will not provide financial guidance for the full year 2026 or host a conference call to discuss the quarterly results. The company cited the pending acquisition by Boston Scientific Corporation (NYSE: BSX) as the reason for suspending these investor communications (8-K filing, 2026-07-30).
MarginX data indicates Penumbra is expected to report third quarter 2026 results on November 3, 2026, though the status of that reporting may depend on the acquisition timeline.
Forward-Looking Risks
The company's forward-looking statements highlighted several acquisition-related risks, including "the risk that the pending acquisition by Boston Scientific Corporation will not be completed in the expected timeframe or at all, including the risk that required regulatory approvals will not be obtained" (8-K filing, 2026-07-30). Penumbra also flagged potential adverse effects to its business during the pendency of the acquisition, such as employee departures or diversion of management's attention.
Recent Insider Activity
MarginX data shows recent insider transactions including a gift of 77,000 shares by Adam Elsesser, a sale of 100 shares by Harpreet Grewal, and a tax withholding of 150 shares by Lambert Shiu.
Penumbra serves healthcare providers in more than 100 countries with a portfolio focused on removing blood clots "from head-to-toe with speed, safety and simplicity," treating conditions including ischemic stroke, pulmonary embolism, and acute limb ischemia (8-K filing, 2026-07-30).
This article was generated by MarginX from the 8-K filing on 2026-07-30. It is not investment advice.